Tag: 2017
ObsEva SA to Attend LEERINK Partners Global Healthcare Conference in NYC
Geneva, Switzerland – February 03, 2017 – ObsEva SA (ObsEva) announced today that Ernest LOUMAYE, M.D., Ph.D., CEO and Co-Founder and Tim ADAMS, CFO, will…
ObsEva SA Announces Pricing of Initial Public Offering
(GLOBE NEWSWIRE via COMTEX) –ObsEva SA / ObsEva SA Announces Pricing of Initial Public Offering . Processed and transmitted by…
ObsEva Expands Leadership Team and Board of Directors with Industry Veterans
Geneva, Switzerland, 17 January 2017 – ObsEva SA (ObsEva), a biopharmaceutical company focused on the development and commercialization of novel therapeutics…
ObsEva Announces Completion of Phase 1 First-in-Women Study of OBE022 for the Treatment of Preterm Labor
– First-in-class orally active prostaglandin F2α receptor antagonist designed to safely control inflammation, uterine contractions, membrane ruptures and cervical changes that…